Related Experiment Video

Updated: Aug 23, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

A pharmacoeconomic evaluation of aggressive cholesterol lowering in Sweden

Anders Olsson1, Roman Casciano, Lee Stern

  • 1Department of Medicine and Care, Faculty of Health Sciences, Linköping University, Linköping, Sweden.

International Journal of Cardiology
|June 19, 2004
PubMed

Insights

Aggressive atorvastatin treatment after acute coronary syndrome in Sweden reduces events and offsets costs. This approach offers clinical benefits with a significant hospitalization cost reduction.

Area of Science:

  • Cardiovascular Medicine
  • Health Economics
  • Pharmacoeconomics

Background:

  • Acute coronary syndrome (ACS) necessitates effective and cost-efficient treatment strategies.
  • Statins, like atorvastatin, are crucial in managing cardiovascular risk post-ACS.
  • Understanding the economic impact of aggressive statin therapy is vital for healthcare systems.

Purpose of the Study:

  • To estimate short-term healthcare costs associated with aggressive atorvastatin treatment in Swedish ACS patients.
  • To determine the incremental cost per event avoided with atorvastatin therapy.
  • To assess the cost-offset from clinical benefits in a Swedish context.

Main Methods:

  • Pharmacoeconomic analysis using data from the MIRACL study and Swedish cost data.
  • Comparison of 16-week healthcare costs between atorvastatin 80 mg/day and placebo groups.
  • Inclusion of direct medical costs and assessment of various clinical outcomes (e.g., death, MI, stroke, revascularization).

Main Results:

  • Atorvastatin reduced the event probability from 40.4% to 36.6% per patient.
  • Incremental cost was SEK 578 per patient, with a cost per event avoided of SEK 15,076.
  • Sixty-six percent of atorvastatin treatment costs were offset by reduced event-related expenditures.

Conclusions:

  • Aggressive short-term atorvastatin treatment post-ACS in Sweden yields significant clinical benefits.
  • These clinical benefits lead to a substantial offset in hospitalization costs.
  • Atorvastatin therapy demonstrates a favorable pharmacoeconomic profile in the Swedish healthcare setting.
Abstract

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...